<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191903</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 16-02</org_study_id>
    <nct_id>NCT03191903</nct_id>
  </id_info>
  <brief_title>Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</brief_title>
  <official_title>Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel group, active comparator
      controlled trial to evaluate the efficacy and safety of a single injection of Cingal for the
      relief of joint pain in subjects with OA of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">April 23, 2018</completion_date>
  <primary_completion_date type="Actual">April 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline WOMAC pain score</measure>
    <time_frame>26 weeks</time_frame>
    <description>• The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 26 weeks post treatment comparing the Cingal group to the TH group.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)</description>
    <arm_group_label>Cingal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monovisc</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
    <arm_group_label>Monovisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide</intervention_name>
    <description>20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <other_name>TH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening Inclusion Criteria

               1. Subject is 40-75 years old, with a Body Mass Index (BMI) ≤ 40 kg/m2.

               2. Subject has Kellgren-Lawrence (K-L) severity grade I, II or III in the index knee
                  as determined by X-ray. Contralateral knee: K-L severity grade 0, I or II.

               3. Subject has had at least two signs and at least two symptoms of OA disease (based
                  on the European League Against Rheumatism (EULAR) recommendations for diagnosing
                  knee OA) in the index knee for at least 6 months despite conservative treatment
                  (weight reduction, physical therapy, pain medications, etc.). The EULAR signs and
                  symptoms are as follows:

                    -  Signs: crepitus, restricted movement and bony enlargement

                    -  Symptoms: persistent knee pain, limited morning stiffness and reduced
                       function

               4. Subject must be willing to abstain from other IA treatments of the knee for the
                  duration of the study.

               5. Subject is willing to discontinue all analgesics including NSAIDs, except
                  acetaminophen/paracetamol, at least seven days before the treatment injection and
                  through the completion of the study.

               6. Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0
                  grams per day per the package insert) for the treatment of joint pain for the
                  duration of the study. At least forty eight hours prior to the Baseline Visit and
                  each follow-up visit, the subject is willing to discontinue use of
                  acetaminophen/paracetamol.

               7. Subject is willing to maintain a stable dose of oral glucosamine and/or
                  chondroitin sulfate products throughout the study, if taken prior to signing the
                  informed consent form (ICF).

               8. Subject is able to understand and comply with the requirements of the study and
                  voluntarily provides consent.

        Exclusion Criteria:

          -  1. Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either
             knee within 6 months of signing the informed consent form (ICF). A subject will be
             excluded if they are planning to receive an HA or steroid injection (other than the
             study injection) in either knee during the course of this study.

             2. Subject had an arthroscopy of either knee within 3 months of signing the ICF.

             3. Subject had an open surgical procedure of either knee or hip or any surgery of the
             spine within 12 months of signing ICF. Subject plans to have knee, hip or spine
             surgery within the study period.

             4. Subject has intra-articular trauma to the index knee. Subject has concurrent
             multi-system or multi-limb trauma.

             5. Subject has evidence or medical history of the following diseases in the index
             knee: septic arthritis; inflammatory joint disease; history of Reiter's syndrome;
             gout; chondrocalcinosis associated with recurrent episodes of acute synovitis of the
             knee consistent with pseudogout; osteochondritis dissecans, Paget disease of the bone;
             ochronosis; acromegaly; hemochromatosis; primary osteochondromatosis; known history of
             Wilson disease; heritable disorders or collagen gene mutations.

             6. Subject has a history of cartilage repair surgery in the index knee within 3 years
             of signing the ICF.

             7. Subject has a history of ACL repair, reconstruction or injury in the index knee
             within 3 years of signing the ICF.

             8. Subject has X-ray findings of acute fractures, severe bone loss, avascular
             necrosis, severe bone or joint deformity in the index knee.

             9. Subject has significant varus or valgus deformity greater than 10 degrees in either
             knee.

             10. Subject has a clinically apparent tense effusion of the index knee. 11. Subject
             has knee instability in either knee per the Investigator's assessment.

             12. Subject requires consistent use of an assistive device (e.g. wheelchair, walker,
             etc.) Occasional use of a cane is acceptable.

             13. Subject has medical condition(s) which could affect study assessments or may
             adversely affect the safety and/or success of the study treatment. This includes but
             is not limited to the following: a. Peripheral neuropathy severe enough to interfere
             with evaluation of the subject, b. Vascular insufficiency severe enough to interfere
             with evaluation of the subject, c. Active fibromyalgia, d. Hemiparesis involving
             either lower extremity, e. Immunocompromised or immunosuppressive disorder or
             receiving medications to treat immunosuppressive disorders, f. Systemic bleeding
             disorder(s), g. Current malignancy or treatment within the last 5 years, except for
             non-melanoma skin cancer, h. Significant psychiatric disorder, i. Active drug and/or
             alcohol abuse within the past year, j. Uncontrolled diabetes with a screening HbA1c of
             &gt;7%.

             14. Subject is taking medications at the time the subjects signs the ICF which could
             interfere with the treatment procedure, healing and/or assessments. This includes but
             is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet
             treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular
             protection is allowed if a stable regimen is maintained for the duration of the study.

             15. Subject is receiving treatment using electromagnetic stimulation and/or low
             intensity ultrasound in the index knee at the time of signing the ICF, within 3 months
             of signing the ICF or plans to receive treatment any time during the study period.

             16. Subjects who had an oral, intramuscular, intravenous, rectal suppository or
             topical (excluded in index knee only) corticosteroid within 30 days of signing the ICF
             are excluded. Topical corticosteroid use at any site other than the index knee is
             allowed.

             17. Subject has a pre-treatment contraindication to IA injections or aspiration of the
             index knee, including cutaneous infection in the injection site area, active IA
             infection (as suggested by moderate or marked effusion), knee deformity or condition
             which, in the opinion of the Investigator could jeopardize the sterility or delivery
             of the IA injection.

             18. Subjects with a history of hypersensitivity to any of the ingredients in the
             hyaluronan or previous hypersensitivity to the administration of corticosteroids or an
             inability to tolerate acetaminophen/paracetamol.

             19. Subject has any contraindication to the receipt of a corticosteroid. 20. Subject
             is receiving or in litigation for worker's compensation. 21. Subject is a woman who is
             pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential
             who refuses to use effective contraception during the course of the study.

             22. Subject was involved in any other research study involving an investigational
             product, or a new application of an approved product, within 60 days of signing the
             ICF.

        Baseline Inclusion Criteria

        1. Subject has a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
        pain-sub-score ≥ 40 mm and ≤ 90 mm in the affected knee and ≤ 30 mm in the contralateral
        knee on a 100 mm Visual Analog Scale (VAS) scale.

        Baseline Exclusion Criteria

          1. Subject has a decrease of ≥ 20 mm in the WOMAC pain-sub-score (average of 5 pain
             scales) from Screening to Baseline in the index knee on a 100 mm Visual Analog Scale
             (VAS) scale.

          2. Subject has a synovial fluid aspirate volume &gt; 20 mL in the index knee.

          3. Subject has a contraindication to continue with the study treatment injection based on
             the visual appearance of the synovial fluid aspirate unless the fluid is examined
             microscopically prior to injection with no clinically significant findings (e.g.
             bacteria, crystals or blood).

          4. Subject has range of motion of less than 100° flexion in either knee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki Hospital, Department of Traumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baleseti Központ</name>
      <address>
        <city>Budapest,</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center of Downtown-Lipotvaros, Orthopedic Outpatient Clinic (Belvárosi-Lipótvárosi Egészségügyi Szolgálat Ortopeadia)</name>
      <address>
        <city>Budapest</city>
        <zip>1051</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>29-41</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE KK Ortopediai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jutrix Medical Llc</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medidea Bt.</name>
      <address>
        <city>Kiskunfélegyháza</city>
        <zip>6100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kastelypark Klinka</name>
      <address>
        <city>Tata</city>
        <zip>2890</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Świętego Łukasza S.A.</name>
      <address>
        <city>Bielsko-Biała</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Medi SPATZ</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTIMED Niepubliczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne 4M Plus</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOVAMED Jackowiak Krajewski Spółka Jawna</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Amed Warszawa Targówek</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Świdnik,</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

